Literature DB >> 1851840

Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition.

G D Zeevalk1, W J Nicklas.   

Abstract

"Graded" metabolic stress was induced chemically in an ex vivo preparation of retina to examine the early events following metabolic inhibition that lead to acute toxicity. Toxicity was assessed histologically and by quantitation of endogenous gamma-aminobutyric acid (GABA) release. Blockade of glycolysis with iodoacetate or electron transport with potassium cyanide for 30 min ("mild" metabolic stress) produced histopathology and GABA release similar to that seen with glutamate agonist treatment. These effects were completely prevented by the N-methyl-D-aspartate (NMDA) antagonist [(+)-5-methyl-10,11-dihydro-5H-dibenzo (a,d)cyclohepten,5,10-imine maleate (MK-801) and occurred in the absence of any net increase in extracellular glutamate or aspartate. More "severe" compromise of metabolism (iodoacetate plus potassium cyanide for 30 min) caused greater swelling and GABA release, which was only partially attenuated by competitive or noncompetitive NMDA antagonists and was accompanied by elevations in extracellular excitatory amino acids. Temporal studies of "severe" metabolic inhibition and the rise in excitatory amino acids demonstrated that, like "mild" metabolic inhibition, the early acute pathology was mediated exclusively by the NMDA receptor and occurred before elevation in excitatory amino acids. Tetrodotoxin and 6-nitro,7-cyanoquinoxaline,2,3-dion (CNQX) had little effect per se on reducing GABA release under conditions of "severe" metabolic inhibition; however, CNQX or tetrodotoxin in combination with MK-801 afforded greater protection than did MK-801 alone. Thus, activity at kainate/AMPA receptors and voltage-sensitive Na+ channels may be additional factors contributing to acute toxicity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851840

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Acquired mitochondrial impairment as a cause of optic nerve disease.

Authors:  A Sadun
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Glutaric aciduria type I: pathomechanisms of neurodegeneration.

Authors:  K Ullrich; B Flott-Rahmel; P Schluff; U Musshoff; A Das; T Lücke; R Steinfeld; E Christensen; C Jakobs; A Ludolph; A Neu; R Röper
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

3.  D-beta-hydroxybutyrate prevents glutamate-mediated lipoperoxidation and neuronal damage elicited during glycolysis inhibition in vivo.

Authors:  Jana Mejía-Toiber; Teresa Montiel; Lourdes Massieu
Journal:  Neurochem Res       Date:  2006-11-18       Impact factor: 3.996

Review 4.  Mitochondrial dysfunction in neurodegeneration.

Authors:  J M Cooper; A H Schapira
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

5.  Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow.

Authors:  G Cohen; R Farooqui; N Kesler
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

6.  Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis.

Authors:  Z Pang; J W Geddes
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

7.  Biochemistry and bioenergetics of glutaryl-CoA dehydrogenase deficiency.

Authors:  S W Sauer
Journal:  J Inherit Metab Dis       Date:  2007-09-21       Impact factor: 4.982

Review 8.  Excitotoxicity, energy metabolism and neurodegeneration.

Authors:  A C Ludolph; M Riepe; K Ullrich
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

9.  Nerve growth factor protects the cortical neurons from chemical hypoxia-induced injury.

Authors:  Li Zhu; Fang Du; Lei Yang; Xiao Mei Wu; Zhong Ming Qian
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

Review 10.  Mouse models of Huntington's disease and methodological considerations for therapeutic trials.

Authors:  Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2009-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.